Cost-Effectiveness of Canakinumab From a Canadian Perspective for Recurrent Cardiovascular Events
CJC Open, 2022 Background: Cardiovascular (CV) disease is a condition with high levels of morbidity and mortality. Canakinumab is a novel monoclonal antibody therapy that has been shown to reduce CV events but is associated with side effects and high cost.
Kevin E. Boczar, MD +3 more
doaj +1 more source
mAbs, 2010 Canakinumab (ACZ885, Ilaris) is a human anti-IL-1beta monoclonal antibody developed by Novartis. Its mode of action is based on the neutralization of IL-1beta signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. In June 2009 the drug was approved by the US Food and Drug Administration for the treatment of
openaire +2 more sources
Targeting inflammation to reduce cardiovascular disease risk [PDF]
, 2017 This joint themed section of the British Journal of Pharmacology and the British Journal of Clinical Pharmacology stems from a joint British Pharmacological Society – Italian Society of Pharmacology symposium held at the 37th National Congress of the ...
Cirino, Guiseppe, Maffia, Pasquale
core +1 more source
Gouty arthritis of the spine in a renal transplant patient : a clinical case report: an unusual presentation of a common disease [PDF]
, 2015 Axial gout is a well-documented but uncommon manifestation of gout. Its mimicking nature and the impracticality of axial joint aspiration might considerably delay its diagnosis.
Dhaese, Sofie +4 more
core +1 more source
Development and Role in Therapy of Canakinumab in Adult-Onset Still's Disease [PDF]
, 2018 Adult-onset Still's disease (AOSD) is a rare inflammatory disease of unknown etiology typically characterized by episodes of spiking fever, evanescent rash, arthralgia, leukocytosis, and hyperferritinemia. The pivotal role of interleukin (IL)-1 and other
Baggio, Chiara +4 more
core +1 more source
Interleukin-1 blockade in recently decompensated systolic heart failure: study design of the recently decompensated heart failure anakinra response trial (RED-HART) [PDF]
, 2015 Heart Failure (HF) is a clinical syndrome characterized by dyspnea, fatigue, and poor exercise capacity due to impaired cardiac function. The incidence of HF is increasing and represents the leading cause of hospitalization in the United States among ...
Abbate Antonio +8 more
core +1 more source
Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms [PDF]
, 2018 Hypertension and type 2 diabetes are common comorbidities. Hypertension is twice as frequent in patients with diabetes compared with those who do not have diabetes.
Guzik, Tomasz J. +2 more
core +1 more source
Efficacy of canakinumab in mild or severe COVID‐19 pneumonia
Immunity, Inflammation and Disease, 2021 Background Clinicians all around the world are currently experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Several therapeutic strategies have been used until now but, to date, there is no specific therapy to
Katia Falasca +9 more
doaj +1 more source
What makes gouty inflammation so variable? [PDF]
, 2017 Acute gout arthritis flares contribute dominantly to gout-specific impaired health-related quality of life, representing a progressively increasing public health problem.
Terkeltaub, Robert
core +2 more sources
Expedited Desensitization to Canakinumab
Allergy & Rhinology, 2020 Introduction Interleukin-1 (IL-1) antagonists have been successful in the management of monogenic auto-inflammatory diseases, notably classic hereditary fever syndromes, such as Familial Mediterranean Fever (FMF). Anakinra (Kineret®), a human recombinant
Neha Sanan DO +3 more
doaj +1 more source